美股新聞 標題聯播 · 近 24 小時 284 則 · 25 個來源 · 最新 9/20 06:32
本站只列標題、來源、時間與原文連結,不重製內文;著作權屬原媒體與原作者。新聞稿通路(PR Newswire、Business Wire、GlobeNewswire)是公司自己發的,屬第一手;媒體是轉述。
全部 · FDMT近 30 天 0 則 · 第 1 / 1 頁
- 4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Tops Revenue Estimates
- 4DMT Reports Second Quarter 2026 Financial Results, Operational Highlights and Expected Upcoming Milestones
- MediWound (MDWD) Reports Q2 Loss, Beats Revenue Estimates
- Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
- Bioventus (BVS) Q2 Earnings Meet Estimates
- Roblox downgraded, Quanta Services upgraded: Wall Street's top analyst calls
- Amneal Pharmaceuticals (AMRX) Q2 Earnings and Revenues Surpass Estimates
- 4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
- 4DMT Announces Presentation at 44th Annual Scientific Meeting of the American Society of Retina Specialists
- 4DMT Completes Enrollment for 4FRONT-2 Global Phase 3 Clinical Trial of 4D-150 in Wet AMD
- 4DMT Secures Strategic Credit Facility for up to $200 Million from Hercules Capital
- Strength Seen in 4D Molecular Therapeutics (FDMT): Can Its 7.9% Jump Turn into More Strength?
- Wet AMD Market Set for Robust Growth Through 2036, Driven by Advancements in Anti-VEGF Therapies | DelveInsight
- 4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates
中文標題是機器翻譯(NLLB 模型,不外送資料),專有名詞靠對照表,語意以英文原題為準。預設藏掉:選股文與自動生成站(Motley Fool、24/7 Wall St、Trefis、MarketBeat…)、加密幣、律師事務所的股東訴訟廣告、非英文、新聞稿裡的人事任命 / 出席活動 / 得獎、個人理財專欄,以及通路稿標題對不到上市公司的。個股標籤是從標題辨識的(通路標準寫法 (NASDAQ: NVDA)、公司名對照);帶「?」的是從摘要辨識、信心較低。來源等級 A / B / C 只影響精選排序,不是對媒體的評價。